GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells (IMAGE)
Caption
Figure 2: GSK inhibitor overcomes BRAF resistance.
GSK3-I (LY2090314) was provided to the A375 melanoma cell line as detailed in the legend of Figure 1. GSK3-I significantly reduced the viability of BRAFi-sensitive (BRAF-S) and BRAFi- resistant (BRAF-R) melanoma cells as assessed by counting the colony-forming units employing the cell viability assay. Bars indicate % cell viability after 3 weeks of treatment with GSK-I as compared to untreated control groups. Results are given as mean ± SD. ****p < 0.00001 by two-way ANOVA.
Credit
Copyright: © 2025 Crisan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Usage Restrictions
With credit to the original source.
License
Original content